By sharing examples on interim analysis, some unresolved issues will be brought up for panel discussion. For example, should the adjusted p-value be reported? How to compute the adjusted p-value and confidence intervals? What significance level should the secondary endpoints be tested at if the trial is stopped early for efficacy? This will serve as the prelude for panel discussion.